TG Therapeutics

UKONIQ™ (umbralisib) FDA Approval

February 8, 2021

TG Therapeutics Conference Call Participants

Prepared Remarks

Introduction

- Jenna Bosco, Senior Vice President, Corporate Communications

Opening Remarks

- Michael S. Weiss, Executive Chairman & Chief Executive Officer

USPI Review

- Owen A. O'Connor, MD, PhD, Chief Scientific Officer

Commercial Launch

- Adam Waldman, Chief Commercialization Officer

Forward Looking Safe Harbor Statement

This presentation contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Such forward looking statements include but are not limited to statements regarding expectations for the timing and commercial launch and availability of UKONIQ™ (umbralisib) for relapsed or refractory (R/R) marginal zone lymphoma (MZL) and follicular lymphoma (FL); clinical trials, including the confirmatory trial for UKONIQ in R/R MZL and FL; and anticipated healthcare professional and patient acceptance and use of UKONIQ for the FDA-approved indications. Factors that could cause our actual results to differ materially include but are not limited to: the Company's ability to establish and maintain a commercial infrastructure, and to successfully launch, market and sell UKONIQ or future products, if approved; failure to obtain and maintain requisite regulatory approvals for UKONIQ or future product candidates; the potential for variation in forecasted projections and estimates about the potential market for the Company's products, including UKONIQ; the risk that the safety and tolerability profile observed with UKONIQ to date may change as additional patients are exposed for longer durations in clinical trials or subsequent to commercialization; the Company's ability to meet post-approval compliance obligations; the Company's reliance on third parties for a range of functions, including manufacturing, for its clinical and commercial products; potential regulatory challenges to the Company's plans to seek expanded or additional indications for UKONIQ in the U.S. or plans to seek marketing approval for the product in additional geographies, outside of the U.S.; the risk that the Company will not be able to meet the clinical trial or regulatory submission timelines projected or achieve other anticipated milestones; the uncertainties inherent in research and development; and the risk that the ongoing COVID-19 pandemic and associated government control measures have an adverse impact on our research and development plans or commercialization efforts.

Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in our other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Michael S. Weiss

Chief Executive Officer

TG Therapeutics

First & Only Targeted Inhibitor of PI3K-delta and CK1-epsilon

UKONIQ is indicated for the treatment of adult patients with:

MZL — R/R MZL who have received at least one prior anti-CD20-based regimen

FL — R/R FL who have received at least three prior lines of systemic therapy

These indications are approved under accelerated approval based on overall response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial.

R/R: relapsed/refractory; MZL: marginal zone lymphoma; FL: follicular lymphoma

Fearless Pursuit of Innovative Solutions for Patients



Owen A. O'Connor, MD, PhD

Chief Scientific Officer

TG Therapeutics

UKONIQ: First & Only Inhibitor of PI3K-δ and CK1-ε



- Pharmacologically distinct from commercially available PI3k inhibitors
- Highly selective to the PI3k-delta isoform with unique inhibition of CK1-epsilon
- Oral once-daily dosing
- Impressive clinical activity as a monotherapy in highly treated patients

Kinase Profiling

Umbralisib



Idelalisib



Duvelisib







Burris, et. al., The Lancet Oncology, February 2018; These findings do not enable safety or efficacy comparisons between these compounds

UKONIQ Label Efficacy Highlights: UNITY-NHL

IRC- Assessed Overall Response Rates (ORR)

MZL



- mDOR[b] not reached (95% CI (9.3-NE); range, 0.0+-21.8+ months) with a median follow-up of 20.3 months (range, 15.0-28.7 mos)

FL



- mDOR[b] was 11.1 months (95% CI (8.3-16.4); range, 0.0+-20.9+ months) with a median follow-up of 20.1 months (range, 13.5-29.6 mos)

[a]Per Independent Review Committee according to Revised International Working Group Criteria. [b]Based on Kaplan-Meier estimation + denotes censored observation

CI: confidence interval; CR: complete response; mDOR: median duration of response; NE: not evaluable; ORR: overall response rate; PR: partial response

UKONIQ (umbralisib) prescribing information 2021

UKONIQ ASH 2020 Data in R/R MZL & FL: UNITY-NHL



No MZL CRs progressed (median follow-up ~27.8 months)

IRC: independent review committee; NE: not estimable; NR: not reached; SLL: small lymphocytic lymphoma
Zinzani, et. al, ASH 2020

UKONIQ Label Safety Highlights

Warnings and Precautions

- **Infections**
- **Neutropenia**
- **Diarrhea or non-infectious colitis**
- **Hepatotoxicity**
- **Severe cutaneous reactions**

The most common adverse reactions (>15%): increased creatinine (79%), diarrhea-colitis (58%, 2%), fatigue (41%), nausea (38%), neutropenia (33%), ALT increase (33%), AST increase (32%), musculoskeletal pain (27%), anemia (27%), thrombocytopenia (26%), upper respiratory tract infection (21%), vomiting (21%), abdominal pain (19%), decreased appetite (19%), and rash (18%)

UKONIQ Safety Highlights

- **Received UKONIQ 800mg once daily**
- **14% discontinuation due to AE**
- **Low rates of immune-mediated toxicities**
- **No boxed warning**
- **No recommended dose adjustments for concomitant medications**

UKONIQ (umbralisib) prescribing information 2021; Most common adverse reactions and discontinuation rate based on pooled safety analysis of 221 patients with R/R MZL and FL

Adam Waldman

Chief Commercialization Officer

TG Therapeutics

MZL and FL are Most Common Forms of Indolent NHL[1]

Unmet Needs[2]

- **Elderly population where tolerability is critical**
- **Indolent lymphomas are not curable;** majority of patients will relapse or become refractory to existing care[2]
- **No standard of care after 1st relapse** as currently available options are sub-optimal[3]

MZL and FL Treatment Options by Line of Therapy[4]



Patient Population

~8,000 - 10,000[4]

Annually treated patients in 2L+ MZL and 4L+ FL

(1) Leukemia & Lymphoma Society. NHL Subtypes. http://www.lls.org/lymphoma/non-hodgkin-lymphoma/diagnosis/nhl-subtypes. Accessed January 19, 2021
(2) Denlinger NM, et al. Cancer Manag Res. 2018;10:615-624
(3) ZS Associates ATU, 2020
(4) Putnam Associates, 2019 and Internal Data

Extensive Customer Feedback Strengthens Confidence in UKONIQ's Differentiated Profile

UKONIQ for Relapsed/Refractory MZL and FL

MOA

First and only dual inhibitor of PI3K-Delta and CK1-Epsilon

TOLERABILITY

Low rates of discontinuation due to adverse events

No boxed warning

EFFICACY

Consistent efficacy across both relapsed/ refractory FL and MZL

EASE OF USE

Once-daily, oral dosing regimen

Keys to a Successful Commercial Launch



Fully-Trained, Uniquely-Designed Field Team to Drive Awareness, Overcome Access Barriers, and Ensure Positive Experience

Best In Class Field Team

Celgene · gsk · TESARO · Bristol Myers Squibb · pharmacyclics

Average 20 Years of Hematology Experience

Average 14 Years of Lymphoma Experience

Strong relationships at key oncology centers

Speed to Launch Strategy

- Highly targeted initial focus on high-volume large community practices and academic centers
- Leverage clinical trial experience at these centers as we transition to commercialization

Built For COVID-19 and Beyond – Flexible Engagement Capabilities and Robust Virtual Platforms

Meeting Customers Where They Need Us to Be

- KOL Broadcasts Through Targeted Networks
- Virtual Speakers Bureau and Engagement Platforms
- Virtual Congresses
- Product Website Launched with Search Engine Optimization
- Digital Non-Personal Promotion Live Upon Approval

Comprehensive Plan to Support Seamless Patient Access

Patient Support Services

- One-on-One Dedicated Support
- Access and Reimbursement Support
- Quick Start and Bridge Programs
- Patient Financial Assistance
- Product and Disease Patient Education

Access

- Account team has actively engaged payers for several months
- UKONIQ coverage expectations are in-line with competitive landscape
- Wholesale acquisition cost of a 30 day supply of UKONIQ is $15,900

Distribution

- UKONIQ will be commercially available within a week of approval
- 3rd Party Logistics Provider is ready to distribute UKONIQ
- Specialty Distributors and Specialty Pharmacy Prepared for Launch

TG PatientSupport™

Ready to Launch UKONIQ, the Next Step in our Journey

TG Therapeutics

- Differentiated product profile providing value to patients and providers
- We have the right people in the right positions
- The first step in our journey to commercialize novel treatments and combinations for B-cell malignancies

Q&A Session

TG Therapeutics

THANK YOU!

TG Therapeutics